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BACKGROUND: Epigenetic changes refer to any herita-
ble modification in gene expression independent of alter-
ations in the DNA sequence. Currently, it is well
established that epigenetics represents a crucial player
for tumor development. Nevertheless, the epigenetic
mechanisms involved in the development and progression
of salivarygland tumors (SGTs) remainpoorlyunderstood.
METHODS: In this study, we analyzed the pattern of
acetyl-histone H3 (lys9) expression in benign and malig-
nant SGTs and further correlate our results with tumors’
proliferative activity and clinical outcomes. We assem-
bled tissue microarrays (TMAs) of 84 cases of SGTs and
analyzed for acetyl-histone H3 (lys9) and Ki-67 using
immunohistochemistry. The study comprised 42 benign
and 42 malignant SGTs.
RESULTS: All cases included in this study were positive
to acetyl-H3 (lys9). We observed that malignant SGTs
were hypoacetylated compared with benign (P = 0.04).
Moreover, acetyl-H3 (lys9) expression was inversely
correlated with Ki67 (**P = 0.02).
CONCLUSION: This study provides the first insight
regarding histone modifications in SGTs. Our results
suggest that epigenetic mechanism, particularly
hypoacetylation of histone H3 (lys9), might play a role
in the behavior of salivary gland tumors. Also, our
findings suggest that interfering with the acetylation
pattern of tumor histones represents a potential novel
therapeutic strategy for the treatment of SGTs.
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Introduction
Salivary gland tumors (SGTs) represent a heterogeneous
group of lesions that account for 5% of all head and neck
neoplasms, with an incidence of 0.4–13.5 cases per 100.000
inhabitants annually (1). Themanagement ofmalignant SGTs
still represents a major challenge in head and neck oncology
due to their biological heterogeneity that leads to an
unpredictable response to therapy. No improvement was
achieved in the overall survival of malignant SGTs over the
last decades. The 5-years survival rate is 60–80%, (2)
although the histological subgrade presents a major impact
in response to therapy leading to 5-years survival rates that
contrast from over 90% in low-grade adenocarcinomas to as
low as 37% in high-grade tumors (1, 3). Moreover, the low
overall survival rates observed in long-term periods demon-
strate thatmore efforts need to be addressed in thisfield. It is of
paramount importance to expand our knowledge regarding
the basic biological and molecular features of SGTs to
identify more efficient therapeutic strategies further. In this
context, epigenetics emerges as a promising field to better
understand the behavior of SGTs, and as a promising target
for therapy, using new developed Epi-drugs. Epigenetic
changes refer to any heritable modification in gene expression
independent of alterations in the DNA sequence. Epigenetic
regulation of gene expression is mediated by DNA methy-
lation, RNA-mediated silencing, and histone modifications,
including lysine acetylation, methylation, and ubiquitination,
serine phosphorylation, and arginine methylation (4). The
dynamic changes in chromatin architecture, which might lead
to modification of the transcriptional activity, are mainly
driven by histone acetylation and deacetylation regulated by
the activity of histone acetyltransferase (HAT) and histone
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deacetylase (HDAC). In histone acetylation, acetyl groups are
added by HAT to the lysine residue resulting in neutralization
of the positive charge in the histone tail leading to a reduced
histone–DNA interaction. This process results in open or
active chromatin structure while the opposite process, of
histone deacetylation, results in chromatin condensation
through the removal of acetyl groups by HDAC (4).
Previous studies established a significant correlation
between histone modifications and tumor development.
Histone deacetylation by HDACs impacts the expression of
several genes involved in tumor initiation and progression
(reviewed in (5)). Indeed, acetylation of histones is
commonly lost in malignant cells when compared to their
normal counterparts (6). The role of histone acetylation and
HDACs, including its prognostic and therapeutic potential,
has been increasingly explored in different types of cancer,
including tumors of glandular origin. It has been demon-
strated that increased expression of HDAC-1 is associated
with higher proliferative capacity in pancreatic adenocarci-
nomas patients (7). Moreover, HDAC inhibitors decrease
cell growth and increase apoptosis of pancreatic adenocar-
cinomas cell lines (8). In breast cancer, the use of HDAC
inhibitors has already been tested in several phase I and II
clinical trials, which revealed encouraging results demon-
strating promising activity in reversing hormone resistance
associated with little adverse effects (9).
In SGTs, other epigenetic events, such as DNA methy-
lation, have been well explored. Most studies focused on
adenoid cystic carcinoma (AdCC) and demonstrated
increased methylation in several tumor suppressor genes
(10). However, the pattern of histone acetylation, in AdCC
as in the other SGTs, remains unexplored. Our group has
deeply investigated the biological and clinical significance
of histone 3 (H3) acetylation at Lys9 (11–13), (L.P. Webber,
V.P. Wagner, M. Curra, P.A. Vargas, L. Meurer, V.C.
Carrard, C.H. Squarize, R.M. Castilho & M.D. Martins,
unpublished data). Functional acetylation of H3 at Lys 9 is
mainly associated with histone deposition, chromatin
assembly, and gene activation (14). Our group demonstrated
that head and neck squamous cell carcinoma cells are
hypoacetylated (12) and this profile is associated with
patients’ poor prognosis (L.P. Webber, V.P. Wagner, M.
Curra, P.A. Vargas, L. Meurer, V.C. Carrard, C.H. Squarize,
R.M. Castilho & M.D. Martins, unpublished data). We also
observed that inhibition of HDAC reduces cisplatin resis-
tance along with a decrease in the number of cancer stem
cells (CSC) of head and neck squamous cell carcinoma (12,
13) and mucoepidermoid carcinoma (11).
The immunohistochemical expression of H3 (lys9)
acetylation has not been investigated in SGTs. Therefore,
the aim of this study was to evaluate the expression pattern
of acetyl-H3 (lys9) in a panel comprising the most common
benign and malignant SGTs. Further, we explored the
correlation of acetyl-H3 (lys9) with lesions’ proliferative
potential through Ki67 immunostaining.
Methods
Study population
Eighty-four formalin-fixed, paraffin-embedded tissue blocks
of SGTs were retrieved from the archives of two Brazilian
pathology services (Piracicaba Dental School—University
of Campinas and Porto Alegre University Hospital—Federal
University of Rio Grande do Sul). Three oral pathologists
reviewed the original hematoxylin–eosin-stained slides and
confirmed the diagnoses according to the World Health
Organization’s 2005 Histological Typing of Salivary Gland
Tumors classification. Clinical data including age, gender,
and tumor localization were retrieved from medical files.
The follow-up period was defined as the time from
diagnosis until the last visit to the hospital or date of death.
This study was approved by the Human Research Ethics
Committee at the Federal University of Rio Grande do Sul
(protocol number 130152/12).
Tissue microarray construction
Tissue microarray (TMA) construction was performed as
previously described and validated (15, 16) by two trained
oral pathologists. Briefly, tumor areas from the central and
most cellular zone of the lesion were selected and marked on
hematoxylin–eosin-stained sections using an objective mar-
ker (NikonCorp, Tokyo, Japan). The slidewas overlaid on the
original paraffin block to determine the matching area to be
used. A manual tissue arrayer (Sakura Co, Japan) was used,
and three representative cylindrical cores of 2.0 mm in
diameter were taken from each tissue block and arranged
sequentially in a ready-to-use recipient paraffin block (Sakura
Co, Japan). Two cores of the normal salivary gland and one
core of oral squamous cell carcinoma were inserted in the left
upper corner of each recipient block for orientation. A map
specifying the precise location of each case was prepared to
allow interpretation of the immunohistochemical results.
Immunohistochemistry
For immunohistochemical staining, TMA samples were
sectioned into 3-lm sections and placed on silanized slides.
Sections were dewaxed in xylene solution and rehydrated in
a descending ethanol series. The avidin–biotin blocking kit
was used to block non-specific binding (Kit Vector
Laboratories, Burlingame, CA, USA). Slides were incubated
overnight with primary antibodies acetyl-H3 (lys9) (C5B11,
1:200; Cell Signaling, Danvers, MA, USA) and Ki67 (MIB-
1, 1:50; Dako, Glostrup, Denmark). Positive reactions were
detected using the chromogen substrate diaminobenzidine
tetrahydrochloride (DAB, Sigma-Aldrich Corp., St. Louis,
MO, USA). Slides were counterstained with Mayer’s
hematoxylin. Sections of oral squamous cell carcinoma
were used as positive controls, and negative controls were
achieved by omitting the primary antibody.
Two pathologists using a double-headed microscope
scored the histone H3 (lys9)-immunostained sections.
Nuclear expression of tumor cells was categorized semi-
quantitatively by percentage of positive cells in a 2009
magnification field, as follows: 1 = 0–50% of positive cells,
2 = 51–100% of positive cells.
Proliferative labeling index (PLI) was determined using
Ki-67-immunostained sections. Images of the selected fields
were captured using a conventional light microscope
(CX41RF model; Olympus Latin America, Inc., Miami,
FL, USA) coupled to a color camera (QColor 5, Coolet,
RTV; Olympus Inc.) and connected to a computer (Dimen-
sion 5150; Dell, Porto Alegre, RS, Brazil). The images were
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analyzed using version 2.18 QCapture software program
(Quantitative Imaging Corporation, Inc., Surrey, DC,
Canada). The total number and percentage of cells present-
ing nuclear positivity were assessed by counting 500 cells at
a magnification of 4009 in each core (3 cores = 1500 cells
per case). The results were expressed as the percentage of
positive cells (mean and standard deviation).
Statistical analysis
All clinical and immunohistochemical data were analyzed
with version 18.0 SPSS for Windows. Chi-square test,
Fisher’s exact test, or Student’s t-test was used to compare
clinicopathological features between benign and malignant
SGTs. Kruskal–Wallis test, Mann–Whitney U-test, chi-
square test, or Fisher’s exact test was used to compare the
immunohistochemical profile of Ki67 and H3 between
benign and malignant SGTs. Spearman’s correlation coef-
ficient was used to examine the relationship between H3 and
Ki67 expression. For all tests, statistical significance was
defined as probability value <0.05.
Results
Clinicopathological aspects differ between benign and
malignant SGTs
Forty-two cases of benign SGTs and 42 malignant SGTs
were included in this study. The cases consisted of 33
pleomorphic adenomas (PA), nine Warthin’s tumor (WT),
22 adenoid cystic carcinomas (AdCC), 15 mucoepidermoid
carcinomas (MEC), and five acinic cell carcinoma (AcCC).
Analyzing the entire cohort of patients, we observed a mean
age at the time of diagnosis of 50.82 (18.08) and a male:
female ratio of 1:1.10. Major salivary glands were affected
in 71.8% of cases (82.14% in the parotid gland and 17.86%
in the submandibular gland). Minor salivary glands were
affected in 28.2% of cases (39.13% in the palate). Table 1
compares the primary clinical data between benign and
malignant SGTs. Benign SGTs were diagnosed in older
patients (P = 0.03—Student’s t-test) and were located
mainly in major salivary glands (P = 0.001—Fisher’s exact
test) when compared to malignant SGTs.
Benign SGTs are hyperacetylated compared with malignant
SGTs
All cases included in this study were positive to acetyl-H3
(lys9). A significant difference was observed between
benign and malignant SGTs (P = 0.04—Fisher’s exact test)
(Fig. 1) (Table 2). Benign SGT showed a higher percentage
of cases presenting acetyl-H3 (lys9) expression in more than
50% of neoplastic cells (Fig. 1—arrows indicate positive
tumor cells), thus suggesting that these lesions were
hyperacetylated compared with malignant SGT. In PA, the
immunopositivity was observed in the majority of both
epithelial luminal duct cells and myoepithelial modified
cells. In WT, despite finding a strong positivity in lymphoid
cells, only epithelial cells were evaluated. We found a
strong positivity in the epithelial cells of WT (Fig. 1A). In
malignant SGTs, however, we noted a decrease in acetyl-H3
(lys9)-positive cells (Fig. 1A—arrowhead indicates nega-
tive tumor cells). We observed that the expression of acetyl-
H3 (lys9) was equally distributed between epithelial and
myoepithelial cells of AdCC, and among epidermoid,
intermediate, and mucous cells of MEC (Fig. 1A). Also,
Among all malignant tumors analyzed, both MEC and
AcCC were the most hypoacetylated compared to AdCC.
However, no significant difference was observed (P = 0.15,
chi-square test). Statistical analysis revealed a higher
percentage of benign SGT presenting acetyl-H3 (lys9)
expression in more than 50% of neoplastic cells (P = 0.04
—Fisher’s exact test) (Fig. 1B).
Acetyl-H3 (lys9) is inversely correlated with proliferative
activity
In this study, benign SGTs showed a smaller PLI compared
with malignant SGTs (Fig. 2A,B mean  SD of
0.67  0.81). We observed that some benign cases were
strictly negative to Ki67. Thus, the PLI ranged from 0 to 2.6
(Fig. 2B). On the other hand, in malignant SGTs, the PLI
ranged from 0.4 to 29.4, with a significantly higher
mean  SD of 8.59  8.2 when compared to benign tumors
(P < 0.001,Mann–WhitneyU-test) (Fig. 2B).Amongmalig-
nant SGTs, MEC had the highest PLI of 16.60  10.04;
however, no significant difference was observed with AdCC
or AcCC (P > 0.05, Kruskal–Wallis) (Fig. 2B). We also
found a significant inverse correlation between acetyl-H3
(lys9) and Ki67 expression in SGT (r = 0.34; P = 0.02)
(Fig. 2C). Therefore, hypoacetylation, represented by the
decrease in acetyl-H3 (lys9) expression, was correlated with
increased proliferative activity.
Histone H3 (lys9) acetylation association with outcome
Information regarding clinical staging and outcome was
available for 22 malignant SGTs. Among those cases, 10
(45.5%) were classified at clinical stage I/II at the time of
diagnosis and 22 (54.5%) at stage III/IV. In advanced cases
(III/IV), 66.7% of patients presented hypoacetylated H3
(Lys9) lesions, compared with 50% in the early cases.
Despite the slight tendency observed, no significant differ-
ence was observed (P = 0.36, Fisher’s exact test). During
the follow-up period (between 4 and 13 years), three
patients deceased, of which 2 (66.7%) presented hypoacety-
lated lesions.
Discussion
SGTs are an extremely heterogeneous group of neoplasms
that raise important awareness for its unpredictable clinical
Table 1 Clinicopathological aspects in benign and malignant SGTs
Benign Malignant P value
Gender (%)
Male 21 (50) 18 (45)
Female 21 (50) 22 (55) 0.66a
Age 54.9 (15.94) 46.55 (19.37) 0.03b
Site (%)
Major 36 (87.8) 20 (54.1)
Minor 5 (12.8) 17 (45.9) 0.001a
Bold values denote significant difference among benign andmalignant SGTs.
aFisher’s exact test.
bStudent’s t-test.
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outcomes (1). Other peculiar characteristics of SGTs, such
as unknown etiological factors (17), increased incidence in
pediatric patients (18), and low survival rates in the long-
term analysis (2), support the concern of health profession-
als. The recent discoveries of specific genetic alterations
have deepened our knowledge about the molecular biology
SGTs (19); nevertheless, targeted therapy still presents a
very limited role in the management of malignant SGTs.
While enough efforts are addressed in the field of genetics,
epigenetics of SGTs remains somewhat obscure. In the
present study, we analyzed for the first time the histone
acetylation profile of most common benign and malignant
SGTs. Our results revealed that malignant tumors are
hypoacetylated and therefore present a more condensed
chromatin compared with benign tumors (Fig. 3).
Moreover, acetylation of H3 (lys9) was inversely correlated
with the proliferative activity of SGTs.
The etiology of cancer was for long associated essentially
with genetic aberrations. However, over the past decades,
epigenetics emerged as a crucial player through tumor
development, allowing the understanding of gene expres-
sion modulation in the absence of DNA sequence alter-
ations. Among epigenetic mechanisms, histone
modifications present a primary role in chromatin stability
and packing, thus controlling gene expression and silencing.
Chromatin decondensation is a key mechanism that guar-
antees gene transcription and repair of the genome, regu-
lated mainly by histone acetylation (4). In the present study,
we observed that most common benign SGTs, PA and WT,
were hyperacetylated compared with malignant SGT.
Global histone acetylation is involved in the process of
cellular differentiation and is often seen downregulated in
pluripotent ES cells. As ES cells undergo differentiation, the
acetylation of histones, more specifically histone H3 at
lysine 9, is observed (20). Indeed, we found that more
differentiated cells, present in benign tumors, present
enhanced acetylation of histones.
On the other hand, malignant tumors showed fewer acetyl-
histone H3 (lys9) expression. Chromatin organization plays
an important role during DNA repair. Histone acetylation
opens chromatin, allowing repair proteins to gain access to the
Figure 1 Immunohistochemical expression of acetyl-histone H3 (lys9) in salivary gland tumors. (A) Two benign salivary gland tumors (pleomorphic
adenoma—PA, Warthin’s tumor—WT) and three malignant salivary gland tumors (adenoid cystic carcinoma—AdCC, mucoepidermoid carcinoma—MEC,
and acinic cell carcinoma—AcCC) are depicted. Note a high number of positive nuclear staining in benign salivary gland tumors (arrow) compared with its
malignant counterpart (arrowhead). (B) Diagram represents benign and malignant tumor samples expressing more than 50% of tumor cells expressing acetyl-
H3 (lys9) (black) or less that 50% of tumor cells expressing acetyl-H3 (lys9) (gray).
Table 2 Expression of acetyl-H3 (Lys9) in SGTs
ac. H3(lys9) PA (%) WT (%) AdCC (%) MEC (%) AcCC (%)
<50% 11 (33.3)a 2 (22.2)a 14 (63.6)b 6 (40)a,b 2 (40)a,b
>50% 28 (66.7) 7 (77.8) 8 (36.4) 9 (60) 3 (60)
Absolute number and percentage of cases according to ac. H3(lys9)
expression.
Different letters denote significant difference among column proportions
(P < 0.05—z-test).
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damage lesion (21). We believe that hypoacetylation of
malignant tumors can operate to favor DNA damage perpet-
uation. Dnmt1 triggers histone deacetylase activity (22) and
suppresses cell differentiation (23), leading to a stem cell
phenotype. It is nowwell established that cancer stem cells are
a major cause of tumor recurrence and metastasis (24) and are
present in malignant SGTs (25, 26). Moreover, our group has
demonstrated that acetyl-histone H3 (lys9) modifications are
an important regulator of aggressiveness and resistance to
cisplatin of head and neck squamous cell carcinoma via
upregulation of the NFjB pathway (13). As for head and neck
squamous cell carcinoma, platinum-based regimens are the
most frequently employed for malignant SGTs (reviewed in
(27)). No benefit, however, has been observed regarding
survival in malignant SGT patients that respond to
chemotherapy compared with those who had no response
(28). The largest phase II trial that evaluated cisplatin in
malignant SGTs revealed low response rates and short
duration (29). The epigenetics modifications observed herein
might indicate a promising target to increase cisplatin
efficiency in malignant SGTs.
An interesting finding of the present study was the inverse
correlation of H3(lys9) acetylation and the proliferative
activity of SGTs. We observed that tumor cells when more
acetylated also demonstrate low proliferation rates. Over-
expression of HDAC-1, which leads to tumor hypoacety-
lation, is associated with increased proliferative activity in
pancreatic adenocarcinomas patients (7). The association of
HDAC and increased proliferation was assessed in breast
cancer, where it was demonstrated that HDAC9 is capable
of regulating key genes such as cell cycle inhibitor
CDKN1A and the pro-apoptotic genes, BAX and DR4, in
addition to SOX9, a gene associated with breast cancer cell
proliferation and metastasis (30). Among the several effects
of HDAC inhibitors, antiproliferative property is achieved
by transcriptional upregulation of the cyclin-dependent
kinase inhibitor p21, independently of p53 status (5).
The study of HDAC inhibitors is moving rapidly into a
new stage of development. To date, three HDAC inhibitors
have been approved by the US-FDA for the treatment of T-
cell lymphoma. Vorinostat (SAHA), approved by the FDA
in October 2006, also demonstrated promising results in
several phase II trials in breast cancer (9). In fact, vorinostat
produced better results when used as a sensitizer to reverse
the resistance of hormone receptors inhibitors (9). Corrob-
orating with this concept of HDAC inhibitors as adjuvant
drugs that prevent chemoresistance, our group demonstrated
that vorinostat inhibits cisplatin resistance in head and neck
cancer cell lines (13). Recently, we showed that vorinostat
administration has a greater impact in mucoepidermoid
cancer stem cells compared with cisplatin alone and
vorinostat plus cisplatin (11). These encouraging results
Figure 2 Correlation between cellular proliferation and histone acetylation in salivary gland tumors. (A) Immunohistochemical staining of Ki-67 in salivary
gland tumors. Note little amount of positive cells present in benign salivary gland tumors (arrow) compared with malignant salivary gland tumors
(arrowhead). (B) Proliferative labeling index (PLI) of each of the salivary gland tumors accordingly to the quantification of Ki-67-positive cells. (C)
Expression of Ki-67 in tumors cells and its correlation with histone acetylation levels (ac. H3 (lys9) in salivary gland tumors.
Figure 3 Schematic illustration of the proposed mechanism of histone
acetylation and tumor proliferation. ac. H3, acetyl-histone H3 (lys9); SGT,
Salivary Gland Tumor.
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show that in malignant SGTs, HDAC inhibitors might be
used both as an adjuvant drug to overcome cisplatin
resistance and as a single-agent therapy. Further studies
are necessary to elucidate this important aspect.
Herein, we provided a comprehensive and novel vision
regarding histone acetylation, a very significant epigenetic
mechanism, in SGTs. Our results demonstrated that malig-
nant SGTs are hypoacetylated, which leads to chromatin
condensation. Moreover, we found that in salivary gland
tumorigenesis, H3 acetylation impacts proliferation in an
inversely proportional manner. Our results represent an
initial step toward understanding epigenetic mechanisms
involved in salivary gland tumorigenesis. We support that
HDAC inhibition might represent a promising target to treat
malignant SGTs.
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